))
Developing Antibodies To Block Neuroinflammation With MindImmune's Stevin Zorn, Ph.D.
Manage episode 515009898 series 3677839
Content provided by Tyler Menichiello. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Tyler Menichiello or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In this episode of "Better Biopharma," host Tyler Menichiello is joined by MindImmune's president and CEO, Stevin Zorn, Ph.D. They discuss the development of the company's lead candidate, MITI-101, a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation linked to Alzheimer's disease.
Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/
Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/
Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions
9 episodes
Share
